Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms.

Abstract

We explored variables associated with patient-reported outcomes (PROs) including symptom burden, impact on daily life and work, obstacles during therapy, satisfaction level with therapy, and health-related quality of life in 1500 respondents with myeloproliferative neoplasms (MPNs) including essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF) in a multicenter, cross-sectional study across China, a representative of the developing countries. In multivariate analyses, urban household registration and higher education level were significantly-associated with no symptoms at diagnosis in respondents with ET or MF. CALR mutation was significantly-associated with lower MPN-10 scores in respondents with MF. Higher MPN-10 scores were significantly-associated with negative impact on daily life and work as well as lower satisfaction level in respondents with ET, PV and MF. Receiving ruxolitinib was significantly-associated with high satisfaction and satisfaction in respondents with MF. In addition, other demographics and clinical variables were also impacting PROs.

• Authors: Dayu Shi, Hongxia Shi, Xiaoli Liu, Minghui Duan, Junling Zhuang, Xin Du, Ling Qin, Wuhan Hui, Rong Liang, Meifang Wang, Ye Chen, Dongyun Li, Wei Yang, Gusheng Tang, Weihua Zhang, Xia Kuang, Wei Su, Yanqiu Han, Limei Chen, Jihong Xu, Zhuogang Liu, Jian Huang, Chunting Zhao, Hongyan Tong, Jianda Hu, Chunyan Chen, Xiequn Chen, Zhijian Xiao, Qian Jiang
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 62 Issue 11 Pg. 2703-2715 (11 2021) ISSN: 1029-2403 [Electronic] United States
• PMID: 34098836 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Topics

• Cross-Sectional Studies
• Humans
• Myeloproliferative Disorders (diagnosis, drug therapy, epidemiology)
• Patient Reported Outcome Measures
• Polycythemia Vera (diagnosis, drug therapy, epidemiology)
• Quality of Life